Neutron therapy for locally advanced head and neck squamous cell carcinoma: optimum dose search.
28 patients with locally advanced primary squamous cell carcinoma of the head and neck received neutron therapy and were randomized between two dose levels: 145 cGy n gamma x twelve fractions, three fractions per week (total 17.4 Gy n gamma). 155 cGy n gamma x twelve fractions, three fractions per week (total 18.6 Gy n gamma). Acute toxicity for skin, mucous membrane, salivary and subcutaneous tissues was graded using the EORTC/RTOG scoring system. Analysis indicates 17.4 Gy n gamma as "safe". A further twelve patients are to be assigned to the higher dose (18.6 Gy n gamma) before making a final dose selection.
Clubb
B
B
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
el-Akkad
S
S
el-Senoussi
M
M
Schultz
H
H
Calkins
J
J
Rymel
J
J
De Vol
E
E
D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D009502:Neutrons / Q000627:therapeutic use*; D010315:Particle Accelerators; D011827:Radiation; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D016032:Randomized Controlled Trials as Topic; D012062:Relative Biological Effectiveness
D003037:Cobalt Radioisotopes